Treatment of Merkel cell carcinoma with radiotherapy and imiquimod (Aldara): A case report

Tumori

Volumn 96, Issue 3, 2010, Pages 508-511

  Balducci, Mario ^a   De Bari, Berardino ^b,c   Manfrida, Stefania ^a   D'Agostino, Giuseppe Roberto ^a   Valentini, Vincenzo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c EA3738   (Italy)

Author keywords

Imiquimod; MCC; Merkel cell carcinoma; Radiotherapy

Indexed keywords

IMIQUIMOD;

AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DERMATITIS; DIABETIC PATIENT; DRUG WITHDRAWAL; GERIATRIC PATIENT; HUMAN; IMMUNOMODULATION; MALE; MERKEL CELL TUMOR; POSTOPERATIVE CARE; RADIATION DOSE; SKIN TOXICITY; SKIN TUMOR; STOMATITIS; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 77954991347     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600324     Document Type: Article

References (22)

1. Toker C: Trabecular carcinoma of the skin. Arch Dermatol, 105: 107-110, 1972.
2. Halperin EC, Perez AD, Brady LW: Perez and Brady's principles and practice of radiation oncology, 5th Ed, p 698, Lippincott Williams and Wilkins, Philadelphia, 2008.
3. Gillenwater AM, Hessel AC, Morrison WH, Burgess M, Silva EG, Roberts D, Goepfert H: Merkel cell carcinoma of the head and neck: effect of surgical excision and radiation on recurrence and survival. Arch Otolaryngol Head Neck Surg, 127: 149-154, 2001.
4. Lewis KG, Weinstock MA, Weaver AL, Otley CC: Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol, 142: 693-700, 2006.
5. Meeuwissen JA, Bourne RG, Kearsley JH: The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma. Int J Radiat Oncol Biol Phys, 31: 325-331, 1995.
6. Mortier L, Mirabel X, Fournier C, Piette F, Lartigau E: Radiotherapy alone for primary Merkel cell carcinoma. Arch Dermatol, 139: 1587-1590, 2003.
7. Pacella J, Ashby M, Ainslie J, Minty C: The role of radiotherapy in the management of primary cutaneous neuroendocrine tumors (Merkel cell or trabecular carcinoma): experience at the Peter MacCallum Cancer Institute (Melbourne, Australia). Int J Radiat Oncol Biol Phys, 14: 1077-1084, 1988.
8. Goessling W, McKee PH, Mayer RJ: Merkel cell carcinoma. J Clin Oncol, 20: 588-598, 2002.
9. Eng TY, Boersma MG, Fuller CD, Cavanaugh SX, Valenzuela F, Herman TS: Treatment of merkel cell carcinoma. Am J Clin Oncol, 27: 576-583, 2004.
10. Greenhalgh T: Narrative based medicine: narrative based medicine in an evidence based world. BMJ, 318: 323-325, 1999.
11. Naldi L, Saurat J-H: Dermatology launches the 'Evidence-Based Case Report' section. Dermatology, 205: 224-225, 2002.
12. Demaria S, Bhardwaj N, McBride WH, Formenti SC: Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys, 63: 655-666, 2005.
13. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D,Weichselbaum R, Hanna N: TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol, 22: 592-601, 2004.
14. Cortesina G, De Stefani A, Majore L, Forni G, Galeazzi E: Loco-regional treatment with low and high doses of interleukin-2 of head and neck squamous cell carcinoma recurrences. Acta Otorhinolaryngol Ital, 14: 3-9, 1994.
15. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, Gilchrist J: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol, 18: 2493-2499, 2000.
16. National Cancer Institute: Merkel Cell Carcinoma Treatment (PDQ®) available at http://www.cancer.gov/cancertopics/pdq/treatment/merk-elcell/ HealthProfessional/page6 (accessed May 18, 2010).
17. Tlsty TD, Hein PW: Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev, 11: 54-9, 2001.
18. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer, 6: 392-401, 2006.
19. Tlsty TD: Tumor stroma and regulation of cancer development. Ann Rev Pathol, 1: 119-150, 2006.
20. Roses RE, Xu M, Koski GK, Czerniecki BJ: Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene, 27: 200-207, 2008.
21. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML: Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol, 41: 1002-1007, 1999.
22. Scott DR: Apparent response of cutaneous Merkel cell tumor to topical imiquimod. Cutis, 77: 109-110, 2006.